Bioverativ will be the name of the standalone biotechnology company created from Biogen’s hemophilia-focused spinoff, and it is expected to launch in early 2017. Bioverativ will be focused on the discovery, research, development and commercialization of treatments for hemophilia and other blood disorders.   “As an independent and focused company, we believe that Bioverativ will be uniquely positioned to drive progress and advance the standard of care for people living with hemophilia,” said Jo...